CPT 81187 CNBP Expanded Sequence Reimbursement

CPT code 81187 represents a laboratory-based molecular diagnostic test that detects expanded sequence alterations in the CNBP (CCHC–type zinc finger nucleic acid–binding protein) gene. This specialized genetic test identifies abnormal alleles involving expanded nucleotide repeats, information that can be clinically significant for diagnosing or characterizing certain neuromuscular and genetic conditions. Nationally, accurate coding and coverage of such molecular diagnostics affect access to precision diagnostics and downstream care decisions.

Key payers covered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. The publication outlines payer coverage considerations, typical sites where the service is performed, and common billing practices tied to laboratory molecular testing.

Readers will learn the clinical context of the test, where it is typically performed, and what to expect in terms of billing classification. The report summarizes benchmarks and policy-relevant points for payers and providers, highlights common modifiers used in laboratory billing when applicable, and provides concise guidance on interpreting the code’s clinical scope. Data not available in the input will be clearly noted where necessary.

Billing Code Overview

CPT code 81187 describes a molecular diagnostic laboratory test performed by a laboratory analyst to detect changes in the gene CCHC–type zinc finger nucleic acid–binding protein (CNBP) and to identify abnormal alleles that involve expanded nucleotide sequences. This service is a genetic testing procedure focused on detecting expanded sequence variants in the CNBP gene.

Service type: Genetic molecular diagnostic testing
Typical site of service: Clinical or reference laboratory performing molecular diagnostics

Clinical Context

A 35-year-old adult with a family history of myotonic dystrophy or clinical features suggestive of a CTG-repeat expansion disorder is referred for molecular testing to detect expanded alleles in the CCHC-type zinc finger nucleic acid–binding protein gene (CNBP). The typical workflow begins with a genetics or neurology clinic visit where the provider documents symptoms (myotonia, muscle weakness, cataracts, cardiac conduction abnormalities) and obtains informed consent for genetic testing. A blood specimen is collected in an appropriate tube and sent to a clinical molecular diagnostics laboratory. In the lab, a molecular technologist or lab analyst performs the technical assay described by 81187 to detect presence and size of expanded repeat sequences in CNBP. Results are interpreted by a molecular pathologist or geneticist who issues a report communicating whether an expanded allele consistent with a pathogenic repeat expansion is present. Typical sites of service include outpatient clinical laboratories, hospital-based molecular labs, or reference diagnostic laboratories. Turnaround time varies from several days to weeks depending on testing methodology (PCR, repeat-primed PCR, Southern blot) and reflex testing requirements.

Coding Specifications

Modifier	Description	When to Use
`26`	Professional component	When billing is split and the reporting provider bills for the professional interpretation only.

Taxonomy Code	Specialty	Notes
207RG0300X	Clinical Molecular Genetics	Providers directing molecular diagnostic testing and interpretation.
2088P0800X	Clinical Pathology	Molecular pathology or laboratory directors overseeing technical testing.
207L00000X	Medical Genetics	Clinical geneticists ordering and integrating results into care plans.
2083P0200X	Neurology	Neurologists commonly order testing for neuromuscular presentations.
207QA0001X	Genetic Counseling	Genetic counselors coordinate testing and provide pre/post-test counseling.

Related Diagnoses

ICD-10 Code	Description	Clinical Relevance
`G71.1`	Myotonic disorders	Primary clinical indication for CNBP (DM2) testing when patients present with myotonia and proximal muscle weakness.
`G72.9`	Myopathy, unspecified	Used when myopathic symptoms prompt genetic evaluation including CNBP expansion testing.
`R25.1`	Tremor, unspecified	Movement symptoms that may overlap with repeat expansion disorders prompting broader genetic testing.
`H26.8`	Other cataract	Early-onset cataracts can be associated with myotonic disorders and support testing.
`I49.9`	Cardiac arrhythmia, unspecified	Conduction abnormalities in patients with suspected myotonic dystrophy warrant genetic confirmation.
`Z13.79`	Encounter for screening for other genetic and chromosomal anomalies	Used for asymptomatic at-risk family members undergoing predictive CNBP testing.
`Z15.01`	Genetic susceptibility to other muscular dystrophy	Family history codes used when ordering targeted genetic testing for known familial CNBP expansions.

Related CPT Codes

CPT Code	Description	Relationship to This Procedure
`81211`	Detection of expanded allele(s) in DMPK (myotonic dystrophy type 1)	Often performed in parallel or sequentially when evaluating myotonic dystrophy spectrum disorders to differentiate DM1 from DM2/DM-like presentations.
`81213`	Detection of expanded allele(s) in ZNF9/CNBP (alternative entry historically)	Historically related nomenclature; testing strategies for CNBP expansions may reference this code in some panels.
`81216`	Detection of expanded allele(s) in HTT (Huntington disease)	Additional trinucleotide repeat testing that may be ordered in differential diagnosis of adult-onset movement or cognitive disorders.
`81162`	Methylation analysis, FMR1 (fragile X)	Repeat expansion testing for other repeat disorders; may be included in broader genetic evaluation when indicated.
`81292`	Genetic testing for repeat disorders panel, targeted	Panel-based approaches to repeat expansion disorders that include CNBP testing; used when multiple loci assessed together.

OpenPayer

Summary & Overview

CPT 81187: CNBP Gene Expanded Sequence Detection